Cersosimo Eugenio, Lee Pearl G, Pandya Naushira
Texas Diabetes Institute, University Health System and the University of Texas Health Science Center at San Antonio, San Antonio, TX.
Division of Geriatric and Palliative Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
Clin Diabetes. 2019 Oct;37(4):357-367. doi: 10.2337/cd18-0074.
The use of long-acting basal insulin analogs is a recommended strategy in older people with diabetes because of their lower risk of hypoglycemia compared to intermediate-acting insulins. In this article, we review the results from recent clinical trials of second-generation basal insulin preparations. We conclude that, although these preparations have improved the management of insulin-requiring older people with type 2 diabetes, there is a need for additional and more specific studies to address the complexities of hyperglycemia management in this population.
由于与中效胰岛素相比，长效基础胰岛素类似物导致低血糖的风险较低，因此在老年糖尿病患者中使用长效基础胰岛素类似物是一种推荐的策略。在本文中，我们回顾了第二代基础胰岛素制剂近期临床试验的结果。我们得出结论，尽管这些制剂改善了需要胰岛素治疗的老年2型糖尿病患者的管理，但仍需要进行更多专门研究，以解决该人群高血糖管理的复杂性问题。
